Pomerantz Law Firm Alerts Investors About Ultragenyx Securities Class Action Lawsuit and Deadlines

Investor Alert: Ultragenyx Pharmaceutical Inc. Class Action Lawsuit

The Pomerantz Law Firm has issued a reminder to investors who have experienced financial losses related to Ultragenyx Pharmaceutical Inc. about a class action lawsuit that has been filed against the company. Investors are urged to take action as the deadlines for participation in this legal process approach.

Background of the Lawsuit

Ultragenyx Pharmaceuticals (NASDAQ: RARE) is a biopharmaceutical company focused on developing innovative products for the treatment of serious rare diseases. However, the company has come under scrutiny concerning allegations of securities fraud and other unlawful business practices. According to the law firm, these actions may have led to significant financial damages for investors involved in trading Ultragenyx securities during the specified class period.

Investors who bought or otherwise acquired shares of Ultragenyx securities between July 9, 2025, and December 29, 2025, may be eligible to join the class action lawsuit. Anyone interested should contact the firm’s representative, Danielle Peyton, at [email protected] or by phone at 646-581-9980. Prospective class members should provide their mailing address and the number of shares purchased for quicker processing and inclusion in the lawsuit.

Key Dates and Developments

The court has established April 6, 2026, as the deadline for investors to request to be appointed as Lead Plaintiff of the class. Those wishing to join the class action but need more information can obtain a copy of the Complaint via the firm's official website at www.pomerantzlaw.com.

Recent events contributed to the plummet of Ultragenyx’s stock price. On July 9, 2025, the company, along with its development partner Mereo BioPharma Group plc, announced the progress of the randomized, placebo-controlled Phase 3 trial of its drug UX143 (setrusumab). Following the report, Ultragenyx's stock price witnessed a significant drop of $10.41 per share, which corresponds to a 25.11% decline the following day. The company's stock continued to suffer after the announcement of failed trial results at the end of December 2025, leading to a further plunge of $14.47 per share or 42.32% on that day.

The Role of Pomerantz LLP

Pomerantz LLP is a prominent law firm with a legacy of pursuing justice in corporate and securities litigation. Founded by Abraham L. Pomerantz, the firm has established itself as a leader in addressing securities fraud and protecting shareholder rights, recovering substantial damages for affected investors. The firm operates from various global locations, including New York, Chicago, Los Angeles, London, and more, ensuring comprehensive support for class members seeking remedy.

It's important for investors to stay informed and aware of the developments regarding this class action lawsuit against Ultragenyx Pharmaceutical Inc. For those who believe they may be affected, the opportunity to join the class is drawing near, emphasizing the necessity for prompt action based on the mentioned deadlines and communication channels.

Conclusion

Investors in Ultragenyx Pharmaceutical Inc. must be vigilant about their rights and actions related to this class action lawsuit. With legal representation from reputable firms such as Pomerantz, affected investors can take steps towards reclaiming losses attributed to the alleged malpractices of the company and its officials. Time is of the essence, as underlining deadlines approach, and timely submissions could enhance their eligibility to participate in this class action lawsuit against the company.